


0967344-081001

The claims have been amended to place them in proper form for U.S. examination. In particular, multiple dependencies have been eliminated. Also, claim 9 has been converted from a European style "use" claim to a method-of-treatment claim in accordance with standard US format. The claim has also been re-worded slightly, to make the claim wording parallel with that of claim 1.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned “Version With Markings To Show Changes”

Respectfully submitted,


James T. Jones
Attorney for Applicant
Reg. No. 30,561

Pfizer Inc
Patent Department
Eastern Point Road
Groton, CT 06340
(860) 441-4903

VERSION WITH MARKINGS TO SHOW CHANGES

In the specification:

The following sentence has been entered as the first paragraph immediately following the title:

This application is filed claiming priority from co-pending United States Provisional Application No. 60/232,669 filed September 15, 2000.

Claim 2 has been canceled.

3. A method or use as claimed in claim 1 [or 2], wherein the inhibitor is administered orally or topically.
4. A method[or use] as claimed in claim 1 [any preceding claim], wherein the [wherein the] inhibitor has an IC50 at less than 100 nanomolar.
6. A method[or use] as claimed in claim 1 [any preceding claim], wherein the inhibitor is sildenafil.
9. A method of treating wounds in a patient which comprises treating the patient with an effective amount [The use] of a cGMP PDE5 inhibitor in combination with a matrix metalloprotease inhibitor (MMP), and/or a urokinase type plasminogen activator inhibitor (uPA), [for the manufacture of a medicament for the treatment of wounds,] wherein the wound type is selected from the following types: chronic venous ulcers, chronic arterial ulcers, chronic decubitus and acute wounds.
10. A method[Use] as claimed in claim 9, wherein the MMP is selected from the group comprising: inhibitors of MMP-3, MMP-12 and MMP-13.

FOOTED "HE 23660